Krsnaa Diagnostics Ltd (KRSNAA) is currently trading at 554.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Krsnaa Diagnostics is an integrated diagnostics provider operating radiology, pathology and teleradiology networks across India under PPP and retail models; the company reports roughly 190 CT/MRI centres, ~140 pathology labs, 4,000+ patient collection centres and has served more than 81 million patients since inception, with presence across 18 states and union territories. Krsnaa’s model is radiology-led and PPP-focused, offering services at prices typically 50–70% below market while maintaining EBITDA and PAT positivity; this unusual combination signals a high-efficiency operating model that leverages scale, accreditation and low customer acquisition costs to serve underserved geographies profitably. The company is amid a tangible capacity ramp: the Rajasthan pathology rollout is expected to contribute about INR200 crore of annualized revenue, Maharashtra CT/MRI expansion and 40+ CT installations are underway, and management expects order completions to push radiology capacity to 200+ centres, creating clear near- to medium-term revenue visibility. Retail diagnostics is rapidly emerging as a second engine of growth: retail revenue grew roughly 8x year-on-year in Q3 and retail touchpoints expanded to over 3,100, with retail now contributing around 8–10% of group revenue and management focused on disciplined customer acquisition to protect unit economics. Krsnaa differentiates through accreditations and quality: India’s first CAP-accredited government pathology lab, an ACR-recognized teleradiology hub, 57 NABL labs and 49 NABH radiology centres strengthen Krsnaa’s credibility with public payors and institutional partners and support scalable clinical governance across a large PPP footprint.

Over the past 52 weeks, Krsnaa Diagnostics Ltd has traded between a low of ₹502.20 and a high of ₹849.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Krsnaa Diagnostics Ltd has a market capitalization of approximately 1,798.40. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Krsnaa Diagnostics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.46 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,798.40 Cr, Krsnaa Diagnostics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Krsnaa Diagnostics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Krsnaa Diagnostics Ltd is 18.46. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

It is proposing to issue up to 16.21 lakh warrants at ₹566 each to the promoter and promoter group, raising up to ₹91.75 crore, convertible into equity shares.

Net profit (attributable to owners) was reported at ₹41.718 crore for Q4 FY26, up 101.75% year-on-year and 173.63% quarter-on-quarter.

The board meeting is scheduled for Thursday, August 13, 2026, as disclosed to BSE and NSE.

Consolidated PAT for Q4 FY26 was ₹41.72 crore, up 101.74% from ₹20.68 crore in Q4 FY25.